Baird raises Mirum Pharmaceuticals stock price target on earnings beat By Investing.com

Baird raised its price target on Mirum Pharmaceuticals to $129 from $112 while keeping an Outperform rating, citing strong Q1 results and continued commercial momentum. Q1 2026 revenue came in at $159.9 million versus $148.8 million expected, a 7.46% beat, though EPS missed at -$13.43 versus -$0.34 due to acquisition-related expenses. Management also lifted full-year 2026 revenue guidance by $30 million, or about 5% on both ends of the range, reinforcing a positive outlook.

Analysis

The market is increasingly treating MIRM as a quality-growth compounder rather than a binary biotech, and that matters because the multiple can re-rate faster than the underlying revenue base. A guidance raise off an already strong quarter reduces the probability that this is just a one-off demand pull-forward; the more important signal is that commercial execution is now supporting a longer-duration cash flow story, which tends to attract non-specialist healthcare growth capital.

Second-order, the acquisition strategy is becoming part of the bull case. If management can keep buying underappreciated assets at reasonable terms and convert them into revenue with limited integration drag, MIRM can keep extending growth without needing a single franchise to do all the work. That creates a compounding effect, but it also raises the bar for capital allocation discipline; one misstep on deal quality or integration would hit both margins and the premium multiple simultaneously.

The main risk is not the next quarter, but the next 2-3 reporting cycles: after a sharp rerating, execution has to stay clean while expectations reset higher. Any deceleration in the core product, reimbursement friction, or acquisition-related margin dilution would likely trigger a faster de-rating than the stock’s historical beta implies. The contrarian view is that the market may be underpricing how much of the good news is already embedded after a 167% move; the opportunity may now be more about timing than direction, with asymmetry improving on pullbacks rather than chasing strength.

If sentiment broadens to include institutional growth buyers, the stock can still overshoot to the upside, but that upside now depends on continued beats and more evidence that new assets are accretive. In other words, the thesis has shifted from ‘can they grow?’ to ‘can they keep surprising?’ — a much harder standard and one that often narrows the margin of safety after the initial rerating.

Key Decisions for Investors

• Maintain/accumulate MIRM on 5-10% post-earnings pullbacks over the next 2-4 weeks; upside remains intact, but entry improves materially if momentum investors de-risk after the recent run.
• Avoid chasing MIRM above prior highs; risk/reward is less favorable now because the stock is increasingly priced for continued execution over the next 2-3 quarters.
• For existing longs, consider financing upside with a covered call structure 1-2 quarters out; this monetizes elevated implied confidence while protecting against a de-rating on any guidance miss.
• Pair idea: long MIRM / short a slower-growth profitable specialty pharma name over the next 3-6 months; the trade works if the market keeps rewarding revenue acceleration and execution quality.
• Set a tactical stop on any long exposure if the company shows acquisition-related margin slippage or core-product growth decelerates for two consecutive quarters; that would likely compress the premium multiple quickly.